Lilly's research on tesamorelin over the past three years has shown sustained benefits for weight loss and diabetes.

The more detailed results of the three-year phase-3 clinical study SURMOUNT-1 conducted by Eli Lilly (LLY.US) show that the active ingredient tirzepatide in the obesity drug Wegovy and the type 2 diabetes drug Ozempic can sustain weight loss and provide benefits in terms of diabetes. After three years, people taking the 15mg dose (the highest dose tested) had an average sustained weight loss of 22.9%. In all three tested doses, tirzepatide was associated with a 94% reduction in the risk of diabetes progression compared to the placebo group. Approximately 1000 patients participating in the trial were considered pre-diabetic patients who were obese or overweight. They were randomly assigned to one of the three doses or the placebo group. Eli Lilly notes that in absolute terms, 99% of patients taking tirzepatide did not develop diabetes within three years. The results of SURMOUNT-1 announced today build on the results published in August.